Literature DB >> 12191472

Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions.

Astrid Lunkes1, Katrin S Lindenberg, Léa Ben-Haïem, Chantal Weber, Didier Devys, G Bernhard Landwehrmeyer, Jean-Louis Mandel, Yvon Trottier.   

Abstract

Proteolytic processing of mutant huntingtin (mhtt) is regarded as a key event in the pathogenesis of Huntington's disease (HD). Mhtt fragments containing a polyglutamine expansion form intracellular inclusions and are more cytotoxic than full-length mhtt. Here, we report that two distinct mhtt fragments, termed cp-A and cp-B, differentially build up nuclear and cytoplasmic inclusions in HD brain and in a cellular model for HD. Cp-A is released by cleavage of htt in a 10 amino acid domain and is the major fragment that aggregates in the nucleus. Furthermore, we provide evidence that cp-A and cp-B are most likely generated by aspartic endopeptidases acting in concert with the proteasome to ensure the normal turnover of htt. These proteolytic processes are thus potential targets for therapeutic intervention in HD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12191472     DOI: 10.1016/s1097-2765(02)00602-0

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  133 in total

1.  Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease.

Authors:  Kuan-Yu Liu; Yu-Chiau Shyu; Brett A Barbaro; Yuan-Ta Lin; Yijuang Chern; Leslie Michels Thompson; Che-Kun James Shen; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-11-14       Impact factor: 6.150

2.  Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.

Authors:  Andrew T N Tebbenkamp; Cameron Green; Guilian Xu; Eileen M Denovan-Wright; Aaron C Rising; Susan E Fromholt; Hilda H Brown; Debbie Swing; Ronald J Mandel; Lino Tessarollo; David R Borchelt
Journal:  Hum Mol Genet       Date:  2011-04-22       Impact factor: 6.150

3.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila.

Authors:  Barbara L Apostol; Alexsey Kazantsev; Simona Raffioni; Katalin Illes; Judit Pallos; Laszlo Bodai; Natalia Slepko; James E Bear; Frank B Gertler; Steven Hersch; David E Housman; J Lawrence Marsh; Leslie Michels Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-01       Impact factor: 11.205

Review 4.  From Alzheimer to Huntington: why is a structural understanding so difficult?

Authors:  Piero Andrea Temussi; Laura Masino; Annalisa Pastore
Journal:  EMBO J       Date:  2003-02-03       Impact factor: 11.598

5.  Targeting expression of expanded polyglutamine proteins to the endoplasmic reticulum or mitochondria prevents their aggregation.

Authors:  Erwann Rousseau; Benjamin Dehay; Léa Ben-Haïem; Yvon Trottier; Michel Morange; Anne Bertolotti
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

6.  Inefficient degradation of truncated polyglutamine proteins by the proteasome.

Authors:  Carina I Holmberg; Kristine E Staniszewski; Kwame N Mensah; Andreas Matouschek; Richard I Morimoto
Journal:  EMBO J       Date:  2004-10-07       Impact factor: 11.598

Review 7.  Polyglutamine toxicity in non-neuronal cells.

Authors:  Jennifer W Bradford; Shihua Li; Xiao-Jiang Li
Journal:  Cell Res       Date:  2010-03-16       Impact factor: 25.617

8.  Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.

Authors:  Juliette Gafni; Theodora Papanikolaou; Francesco Degiacomo; Jennifer Holcomb; Sylvia Chen; Liliana Menalled; Andrea Kudwa; Jon Fitzpatrick; Sam Miller; Sylvie Ramboz; Pasi I Tuunanen; Kimmo K Lehtimäki; X William Yang; Larry Park; Seung Kwak; David Howland; Hyunsun Park; Lisa M Ellerby
Journal:  J Neurosci       Date:  2012-05-30       Impact factor: 6.167

Review 9.  Aggregation of expanded huntingtin in the brains of patients with Huntington disease.

Authors:  Guylaine Hoffner; Sylvie Souès; Philippe Djian
Journal:  Prion       Date:  2007 Jan-Mar       Impact factor: 3.931

Review 10.  A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules.

Authors:  Motomasa Tanaka; Yoko Machida; Nobuyuki Nukina
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.